Search Result

Results for "

Hdac6 selective Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HDAC (151) Akt (1) Aminopeptidase (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (51) Autophagy (11) Bcl-2 Family (1) Beta-lactamase (10) c-Myc (1) Caspase (6) Cholinesterase (ChE) (1) Collagen (1) DNA/RNA Synthesis (1) Epoxide Hydrolase (1) ERK (1) FLT3 (1) Free Fatty Acid Receptor (1) Fungal (1) G Protein-coupled Receptor Kinase (GRK) (1) HCV (1) Histone Methyltransferase (2) HSP (1) Interleukin Related (4) Keap1-Nrf2 (1) MDM-2/p53 (1) Microtubule/Tubulin (18) Necroptosis (1) NF-κB (2) NO Synthase (1) NOD-like Receptor (NLR) (3) Oxidative Phosphorylation (1) p38 MAPK (2) PANoptosis (1) PARP (1) PERK (1) PI3K (1) Pim (2) PPAR (1) PROTACs (3) Proteasome (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (3) Reference Standards (6) Tau Protein (1) TNF Receptor (2) VD/VDR (1) VEGFR (2) Virus Protease (3) Wee1 (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (117) Cardiovascular Disease (4) Endocrinology (1) Infection (4) Inflammation/Immunology (19) Metabolic Disease (1) Neurological Disease (22)

By Targets:

HDAC (151)

Akt (1)

Aminopeptidase (2)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (51)

Autophagy (11)

Bcl-2 Family (1)

Beta-lactamase (10)

c-Myc (1)

Caspase (6)

Cholinesterase (ChE) (1)

Collagen (1)

DNA/RNA Synthesis (1)

Epoxide Hydrolase (1)

ERK (1)

FLT3 (1)

Free Fatty Acid Receptor (1)

Fungal (1)

G Protein-coupled Receptor Kinase (GRK) (1)

HCV (1)

Histone Methyltransferase (2)

HSP (1)

Interleukin Related (4)

Keap1-Nrf2 (1)

MDM-2/p53 (1)

Microtubule/Tubulin (18)

Necroptosis (1)

NF-κB (2)

NO Synthase (1)

NOD-like Receptor (NLR) (3)

Oxidative Phosphorylation (1)

p38 MAPK (2)

PANoptosis (1)

PARP (1)

PERK (1)

PI3K (1)

Pim (2)

PPAR (1)

PROTACs (3)

Proteasome (1)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (6)

Tau Protein (1)

TNF Receptor (2)

VD/VDR (1)

VEGFR (2)

Virus Protease (3)

Wee1 (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (117)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (19)

Metabolic Disease (1)

Neurological Disease (22)

151

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

GMP Molecules

Targets Recommended: HDAC Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16026

Ricolinostat Maximum Cited Publications 43 Publications Verification ACY-1215; Rocilinostat	HDAC Apoptosis	Cancer
Ricolinostat (ACY-1215) is a potent and selective *HDAC6* inhibitor, with an IC₅₀ of 5 nM. ACY-1215 also inhibits *HDAC1, HDAC2, and HDAC3* with IC₅₀s of 58, 48, and 51 nM, respectively.

HY-13271A

Tubastatin A 35+ Cited Publications	Beta-lactamase HDAC Autophagy Apoptosis	Cancer
Tubastatin A is a potent and selective *HDAC6* inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-13428

Tubacin 20+ Cited Publications	Beta-lactamase HDAC Virus Protease	Cancer
Tubacin is a potent and selective inhibitor of *HDAC6, with an IC₅₀* value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-13271

Tubastatin A Hydrochloride 35+ Cited Publications Tubastatin A HCl; TSA HCl	Beta-lactamase HDAC Autophagy Apoptosis	Cancer
Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective *HDAC6* inhibitor with IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-15994

Citarinostat 3 Publications Verification ACY241	HDAC	Cancer
Citarinostat (ACY241) is a second generation potent, orally active and high-selective *HDAC6* inhibitor with an IC₅₀ of 2.6 nM (IC₅₀s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects .

HY-16699

Nexturastat A 3 Publications Verification	HDAC	Cancer
Nexturastat A is a potent, selective *HDAC6* inhibitor. Nexturastat A has inhibitory for HDAC6 with an IC₅₀ of 5 nM. Nexturastat A can be used for the research of multiple myeloma (MM) .

HY-B0494

Bufexamac 2 Publications Verification Bufexamic acid	HDAC Aminopeptidase	Inflammation/Immunology Cancer
Bufexamac is a selective Ⅱb HDAC (HDAC6, HDAC10) and LTA4H dual inhibitor, with K_ds of 0.53 µM and 0.22 µM for *HDAC6* and *HDAC10. Bufexamac is a nonsteroida anti-inflammatory* drug .

HY-19327

ACY-738 5 Publications Verification	HDAC	Cancer
ACY-738 is a potent, selective and orally-bioavailable *HDAC6* inhibitor, with an IC₅₀ of 1.7 nM; ACY-738 also inhibits HDAC1, HDAC2, and HDAC3, with IC₅₀s of 94, 128, and 218 nM.

HY-19328

ACY-775 2 Publications Verification	HDAC	Cardiovascular Disease Neurological Disease
ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC₅₀ of 7.5 nM . ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .

HY-138799

KA2507	HDAC	Cancer
KA2507 is a potent, orally active and selective *HDAC6* inhibitor, with an IC₅₀ of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models .

HY-18700

BRD73954 4 Publications Verification	HDAC	Cancer
BRD73954 is a potent *HDAC* inhibitor and selectively inhibiting both HDAC6 and HDAC8 with IC₅₀ values of 0.0036, 0.12, 9, 12, 23 µM for HDAC6, HDAC8, HDAC2, HDAC1 and HDAC3, respectively. BRD73954 decreases the levels of HDAC6, associated with upregulation of Ac-Tubulin .

HY-111791

ACY-1083 1 Publications Verification	HDAC	Cancer
ACY-1083 is a selective and brain-penetrating *HDAC6* inhibitor with an IC₅₀ of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy .

HY-115475

SW-100 4 Publications Verification	HDAC	Neurological Disease
SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC₅₀ of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier .

HY-135714

Bavarostat EKZ-001	HDAC Microtubule/Tubulin	Neurological Disease Cancer
Bavarostat (EKZ-001) is a blood-brain barrier-permeable, potent *HDAC6* inhibitor and PET radiotracer, with an IC₅₀ as low as 17 nM against human HDAC6. Bavarostat can be labeled with ¹⁸F and used as a probe to map HDAC6 distribution and measure target occupancy in the brains of non-human primates. Bavarostat also selectively modulates tubulin acetylation, but not histone acetylation. Bavarostat is applicable for research on Alzheimer's disease, other neurodegenerative disorders, and cancers .

HY-126330

SS-208 AVS100	HDAC	Cancer
SS-208 is a selective *HDAC6* inhibitor, with an IC₅₀ of 12 nM. SS-208 possesses anti-tumor activity in melanoma .

HY-126147

J22352	HDAC	Cancer
J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective *HDAC6* inhibitor with an IC₅₀ value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1 .

HY-111818

TH34 1 Publications Verification	HDAC	Cancer
TH34, an *HDAC6*/8/10 inhibitor with IC₅₀s of 4.6 μM, 1.9 μM, and 7.7 μM respectively, shows high selectivity over HDAC1/2/3 .

HY-13267

Droxinostat 3 Publications Verification NS 41080	HDAC Apoptosis	Cancer
Droxinostat (NS 41080) is a histone deacetylase (HDAC) inhibitor. Droxinostat selectively inhibits HDAC3, HDAC6, and HDAC8 with IC₅₀ values of 16.9 μM, 2.47 μM, and 1.46 μM, respectively. Droxinostat can be used for the research of hepatocellular carcinoma (HCC) .

HY-153392

TYA-018	Oxidative Phosphorylation HDAC	Cardiovascular Disease
TYA-018 is an orally active, potent and highly selective *HDAC6* inhibitor. TYA-018 can protect heart function in mice. TYA-018 also enhances energetics in mice by increasing expression of targets associated with fatty acid metabolism, protein metabolism, and oxidative phosphorylation .

HY-19747

HPOB 3 Publications Verification	HDAC Apoptosis	Cancer
HPOB is a highly potent and selective inhibitor of *HDAC6* with an IC₅₀ of 56 nM. HPOB displays >30 fold less potent against other HDACs. HPOB enhances the effectiveness of DNA-damaging anticancer agents in transformed cells but not normal cells. HPOB does not block the ubiquitin-binding activity of HDAC6 .

HY-123976

MPT0G211 1 Publications Verification	HDAC	Neurological Disease Cancer
MPT0G211 is a potent, orally active and selective *HDAC6* inhibitor (IC₅₀=0.291 nM). MPT0G211 displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier. MPT0G211 ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 has anti-metastatic and neuroprotective effects. Anticancer activities .

HY-18712

BG45 4 Publications Verification	HDAC Apoptosis Caspase	Cancer
BG45 is a potent *HDAC3* inhibitor with IC₅₀ values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis .

HY-130493

HPB Hdac6 inhibitor HPB	HDAC	Cancer
HPB (HDAC6 inhibitor HPB) is a selective *HDAC6* inhibitor with an IC₅₀ of 31 nM. HPB exhibits >30-flod selectivity for HDAC6 over HDAC1 .

HY-100871

WT-161 5+ Cited Publications	Beta-lactamase HDAC Apoptosis	Cancer
WT-161 is a potent and selective *HDAC6* inhibitor with an IC₅₀ of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .

HY-135890

CG347B 2 Publications Verification	HDAC	Neurological Disease Inflammation/Immunology Cancer
CG347B is a selective *HDAC6* inhibitor, also involves in synthesis of other metalloenzyme inhibitors. *HDAC6* inhibitors can be used for oncology, immunology, and neurology research .

HY-171140

PROTAC HDAC6 degrader 3	PROTACs HDAC	Cancer
PROTAC HDAC6 degrader 3 (Compound 4) is a selective inhibitor and degrader for *HDAC6* with an IC₅₀ of 686 nM and a DC₅₀ of 171 nM. PROTAC HDAC6 degrader 3 promotes the acetylation of α-tubulin . (Pink: ligand for target protein (HY-171141); Blue: ligand for E3 ligase VHL (HY-150803))

HY-161304

HDAC6-IN-33	HDAC	Cancer
HDAC6-IN-33 (compound 6) is a selective and irreversible *HDAC6* inhibitor with an IC₅₀ of 193 nM. HDAC6-IN-33 shows no activity against HDAC1-4. HDAC6-IN-33 is a tight-binding HDAC6 inhibitor capable of inhibiting HDAC6 via a two-step slow-binding mechanism .

HY-159109

HDAC6-IN-46	HDAC	Neurological Disease
HDAC6-IN-46 (compound 12) is a selective histone deacetylase 6 (HDAC6) inhibitor with an IC₅₀ value of 6.2 nM. HDAC6-IN-46 can be used in Alzheimer's disease research .

HY-120448

QTX125	HDAC Apoptosis	Cancer
QTX125 is a potent and highly selective *HDAC6* inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects .

HY-128763

HDAC-IN-4	HDAC	Cancer
HDAC-IN-4 is a selective *HDAC6* and *HDAC10* inhibitor with pIC₅₀s of 7.2 and 6.8 in BRET assay, respectively. Antitumoral activity .

HY-149966

PB131	HDAC	Inflammation/Immunology
PB131 is a selective and brain-permeable *HDAC6* inhibitor with high binding affinity (IC₅₀: 1.8 nM). PB131 has potent anti-inflammatory activity. PB131 can be used for research of inflammation, especially neuroinflammation .

HY-117554

BRD9757	HDAC	Cancer
BRD9757 is a potent, capless and selective *HDAC6* inhibitor with an IC₅₀ of 30 nM. BRD9757 shows excellent selectivity toward HDAC6 versus the class I (>20-fold) and class II (>400-fold) HDACs .

HY-18947

SKLB-23bb	HDAC	Cancer
SKLB-23bb is a potent and selective inhibitor for *HDAC6* with an IC₅₀ of 17 nM and shows 25-fold and 200-fold selectivity relative to *HDAC1* (IC₅₀=422 nM) and *HDAC8* (IC₅₀=3398 nM), respectively.

HY-113957

MPI_5a	HDAC	Cancer
MPI_5a is a potent and selective *HDAC6* inhibitor (IC₅₀=36 nM). MPI_5a weakly inhibits other HDAC isoforms. MPI_5a inhibits acyl-tubulin accumulation in cells with an IC₅₀ value of 210 nM .

HY-150595

HDAC6-IN-10	HDAC Microtubule/Tubulin	Cancer
HDAC6-IN-10 is a highly selective *HDAC6* inhibitor with the IC₅₀ of 0.73 nM. HDAC6-IN-10 has 144~10941-fold selectivity over other HDAC isoforms. HDAC6-IN-10 shows anti-proliferative activities against multiple myeloma cells .

HY-15144B

(S)-Trichostatin A (S)-TSA	HDAC	Cancer
(S)-Trichostatin A ((S)-TSA) is a *HDAC6*-selective inhibitor with IC₅₀s of 9.88 nM and 11.1 nM for Zebrafish HDAC6 and Human HDAC6, respectively. (S)-Trichostatin A weakly inhibits other human HDACs .

HY-178351

HDAC6-IN-67	HDAC Microtubule/Tubulin Apoptosis Caspase Bcl-2 Family	Cancer
HDAC6-IN-67 is a selective *HDAC6* inhibitor (IC50 = 17.15 nM) that exhibits 19-fold selectivity over HDAC1. HDAC6-IN-67 selectively inhibits HDAC6 by interacting with Ser531 and His614. HDAC6-IN-67 induces apoptosis by inducing the cleavage of caspases 9, 8, 3, and PARP, upregulating Bax expression, and downregulating Bcl-2 expression. HDAC6-IN-67 effectively induces the acetylation of α-tubulin, without affecting histone H3 acetylation in MCF-7/ADR cells. HDAC6-IN-67 can be used for the study of breast cancer .

HY-176733

HDAC6-IN-61	HDAC Free Fatty Acid Receptor Microtubule/Tubulin ERK	Neurological Disease
HDAC6-IN-61 (Compound 4e) is a *HDAC6* inhibitor (IC₅₀: 73 nM) with selectivity over other HDAC isoforms. HDAC6-IN-61 is also a GPR40 activator. HDAC6-IN-61 increases acetylated tubulin and ERK phosphorylation levels. HDAC6-IN-61 can be used for research of neuroinflammation such as Alzheimer's disease .

HY-123971

HDAC6 degrader-4	HDAC PROTACs	Cancer
HDAC6 degrader-4 is a PROTAC and a selective *HDAC6* degrader consists of a non-selective HDAC inhibitor and thalidomide-type E3 ligase ligand. HDAC6 degrader-4 can be used for cancer research .

HY-178333

HDAC6-IN-66	HDAC	Cancer
HDAC6-IN-66 is a potent and selective histone deacetylase (HDAC) 6 inhibitor with an IC₅₀ of 1.8 nM. HDAC6-IN-66 induces α-tubulin acetylation over histone H3. HDAC6-IN-66 can be used for the research of cancer .

HY-147731

HDAC6-IN-9	HDAC	Cancer
HDAC6-IN-9 (compound 12c) is a potent and selective *HDAC6* inhibitor with IC₅₀ values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities .

HY-151261

HDAC6-IN-13	HDAC	Inflammation/Immunology
HDAC6-IN-13 (Compound 35m) is a potent, highly selective, orally active *HDAC6* inhibitor with an IC₅₀ of 0.019 μM. HDAC6-IN-13 also inhibits *HDAC1, HDAC2* and *HDAC3* with IC₅₀s of 1.53, 2.06 and 1.03 μM, respectively. HDAC6-IN-13 shows significant BBB permeability and anti-inflammatory activity .

HY-178110

HDAC6-IN-65	HDAC Microtubule/Tubulin Histone Methyltransferase	Cancer
HDAC6-IN-65 is a selective *HDAC6 inhibitor* (IC₅₀ = 0.9 nM) and also exhibits a certain suppressive effect on *HDAC3* (IC₅₀ = 39.4 nM). HDAC6-IN-65 can induce the accumulation of α-tubulin (ac-tubulin) and acetylated histone H3 (ac-histone H3, a class I HDAC inhibition marker) in Neuro-2a cells. HDAC6-IN-65 can be used for the study of melanoma .

HY-161783

HDAC6-IN-45	HDAC Keap1-Nrf2 Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease
HDAC6-IN-45 (Compound 15) is a selective inhibitor for *HDAC6* with IC₅₀ of 15.2 nM. HDAC6-IN-45 exhibits neurotrophic through the upregulation of GAP43 and Beta-3 tubulin markers. HDAC6-IN-45 activates the Nrf2 signaling pathway, reduces H₂O₂-induced ROS production, inhibits apoptosis in PC12, and exhibits neuroprotective efficacy in SCOP-induced zebrafish Alzheimer's Disease models. HDAC6-IN-45 exhibits antioxidant activity and good blood-brain barrier (BBB) permeability .

HY-146293

HDAC6/HSP90-IN-1	HDAC HSP	Cancer
HDAC6/HSP90-IN-1 (compound 17) is a potent and selective dual inhibitor of *HDAC6* and HSP90, with IC₅₀ values of 4.3 and 46.8 nM, respectively. HDAC6/HSP90-IN-1 down-regulates PD-L1 expression in INF-γ treated H1975 lung cancer cells. HDAC6/HSP90-IN-1 inhibits tumor growth in human H1975 xenograft mice .

HY-179421

PROTAC HDAC6 degrader 7	PROTACs HDAC NF-κB NOD-like Receptor (NLR) Interleukin Related TNF Receptor	Inflammation/Immunology
PROTAC HDAC6 degrader 7 is an orally active, highly efficient, and selective PROTAC degrader targeting histone deacetylase 6 (HDAC6) (IC₅₀ = 118 nM). PROTAC HDAC6 degrader 7 can eliminate both the catalytic and zinc-finger ubiquitin-binding domain. PROTAC HDAC6 degrader 7 inhibits NLRP3 inflammasome assembly and activation, as well as blocks NF-κB signaling, thereby reducing the transcription and release of key inflammatory factors. PROTAC HDAC6 degrader 7 can reduce the mRNA levels of NLRP3, pro-IL-1β, TNF-α, and IL-6. PROTAC HDAC6 degrader 7 can be used for the study of inflammatory bowel disease (IBD) .

HY-151569

SAHA-OH	HDAC Apoptosis	Inflammation/Immunology
SAHA-OH is a selective *HDAC6* inhibitor (IC₅₀=23 nM), shows a 10- to 47-fold selectivity for HDAC6 compared to HDAC 1, 2, 3, and 8. SAHA-OH shows anti-inflammatory activity, and attenuates macrophage apoptosis .

HY-161306

ITF5924	HDAC	Cancer
ITF5924 (compound 1) is a potent and highly selective *HDAC6* inhibitor with an IC₅₀ of 7.7 nM. ITF5924 shows greater than 104-fold selectivity for HDAC6 over all other HDAC subtypes. ITF5924 containing a difluoromethyl-1,3,4-oxadiazole (DFMO) moiety is slow-binding substrate analog of HDAC6 that undergo an enzyme-catalyzed ring opening reaction, forming a tight and long-lived enzyme-inhibitor complex .

HY-107550

NCT-14b	HDAC	Cancer
NCT-14b is a *HDAC6*-selective inhibitor. NCT-14b blocks the growth of estrogen receptor α-positive breast cancer MCF-7 cells .

HY-151896

HDAC6-IN-14	HDAC	Cancer
HDAC6-IN-14 is a highly selective *HDAC6* (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

Cat. No.	Product Name	Type

HY-13271AG

Tubastatin A

Fluorescent Dyes

Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective HDAC6 inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

Cat. No.	Product Name	Type

HY-13271AG

Tubastatin A

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N13121

Daphnegiravone D	Flavonoids Flavones Thymelaeaceae Daphne giraldii Nitsche Plants Source Classification	HDAC Apoptosis p38 MAPK
Daphnegiravone D (compound 70) is an HDAC6 inhibitor with anti-hepatocellular carcinoma activity. Daphnegiravone D can induce apoptosis and selectively inhibit the proliferation of liver cancer cells through the p38 and JNK MAPK pathways .

Targets Recommended: HDAC Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13271AG

Tubastatin A	HDAC Beta-lactamase Autophagy Apoptosis	Cancer
Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective *HDAC6* inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits *HDAC10* and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Hdac6 selective Inhibitors

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

GMP Molecules

Natural
Products